Key result
Endothelial ALK1 inhibition reduces LDL transcytosis and atherosclerotic plaque formation in mice without altering lipids.
Answers are grounded in this paper and cite their sources.
Low-density lipoprotein (LDL) accumulation in the arterial wall contributes to atherosclerosis initiation and progression 1 . Activin A receptor-like type 1 (ACVRL1, called activin-like kinase receptor (ALK1)) is a recently identified receptor that mediates LDL entry and transcytosis in endothelial cells (ECs) 2,3 . However, the role of this pathway in vivo is not yet known. In the present study, we show that genetic deletion of ALK1 in arterial ECs of mice substantially limits LDL accumulation, macrophage infiltration and atherosclerosis without affecting cholesterol or triglyceride levels. Moreover, a selective monoclonal antibody binding ALK1 efficiently blocked LDL transcytosis, but not bone morphogenetic protein-9 (BMP9) signaling, dramatically reducing plaque formation in LDL receptor knockout mice fed a high-fat diet. Thus, our results demonstrate that blocking LDL transcytosis into the endothelium may be a promising therapeutic strategy that targets the initiating event of atherosclerotic cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2023) studied Atherosclerosis. Genetic deletion of ALK1 or selective monoclonal antibody against ALK1 was evaluated on LDL transcytosis, arterial LDL accumulation, macrophage infiltration, and atherosclerotic plaque formation. Genetic deletion or monoclonal antibody neutralization of endothelial ALK1 substantially reduced LDL transcytosis and atherosclerotic plaque formation in mice without altering lipid levels.
Synapse has enriched 10 related papers. Consider them for comparative context: